Forest Laboratories, Inc. announced the U.S. Food and Drug Administration (FDA) approval for the Company's supplemental New Drug Application (sNDA) for Lexapro (escitalopram oxalate). The drug is beneficial for the acute and maintenance treatment of Major Depressive Disorder (MDD) in adolescents, 12 - 17 years of age. Lexapro is only the second antidepressant to be approved by the FDA for the treatment of MDD in adolescents, a medical condition that affecting millions of adolescents.

Howard Solomon, Chairman and Chief Executive Officer, of Forest said, "Major depressive disorder in adolescents is a debilitating, but treatable illness. We have long believed that Lexapro would be of benefit for the treatment of depression in adolescents and that is why we undertook the several studies described in the package insert. We are enormously gratified that Lexapro will be available for depressed adolescents who so much require the benefits which Lexapro has made available for depressed adults for the past seven years."

Comments

Search RSS

All rights reserved."